Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06782100 · ClinicalTrials.gov registry record

MRI Guided Management of Occlusive Peripheral Arterial Disease

A clinical trial of Peripheral Vascular Diseases, sponsored by The Methodist Hospital Research Institute.

Recruiting
Registry status
175
Enrollment target
1
Study location

NCT06782100: Recruiting study of Peripheral Vascular Diseases, sponsored by The Methodist Hospital Research Institute.

NCT06782100 is a study of Peripheral Vascular Diseases that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 175 participants, below the 487-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06782100, a study of Peripheral Vascular Diseases, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.

RECRUITING
Registry status
175 participants
Enrollment target
1
Study location

Study Summary

The goal of this observational study is to identify which plaque lesions in patients with peripheral arterial disease are impenetrable and to determine which devices minimize vessel wall injury. Patients undergoing intervention will have an MRI scan prior to their planned percutaneous vascular intervention to assess the plaque and predict procedural difficulty. Patients undergoing lower limb amputation due to peripheral arterial disease will have their limbs included into a second arm of the study The limb will undergo an MRI scan to assess the plaque. The investigator will then test two different devices and assess the effects of these devices on the vessel wall.

Primary Outcome

PVI failure due to inability to cross the target plaque with a guidewire.

Study Locations (1)

Texas

  • Houston Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2024-07-01
Est. Completion 2029-06

What NCT06782100 shows while recruiting

NCT06782100 is an observational study that tracks outcomes without assigning an intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 487-participant average among 19 other Peripheral Vascular Diseases trials with a reported enrollment target (64% lower).

The record links to 1 condition, with Peripheral Vascular Diseases appearing as the primary indexed condition, and to 0 interventions.

NCT06782100 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06782100 about?

NCT06782100 is a clinical study titled "MRI Guided Management of Occlusive Peripheral Arterial Disease". The goal of this observational study is to identify which plaque lesions in patients with peripheral arterial disease are impenetrable and to determine which devices minimize vessel wall injury. Patients undergoing intervention will have an MRI scan prior to their planned percutaneous vascular inte...

What is the current status of trial NCT06782100?

This trial is currently recruiting. The enrollment target is 175 participants. The study started on 2024-07-01. Estimated completion is 2029-06.

What conditions does trial NCT06782100 study?

This clinical trial studies the following conditions: Peripheral Vascular Diseases.

Who is sponsoring clinical trial NCT06782100?

This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06782100 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Vascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06782100's enrollment target sits among peer trials

175 11th of 19 higher than 9 of 19 other Peripheral Vascular Diseases trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Vascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04722341 · 175 participants · NA

    Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

  • NCT05094037 · 175 participants · NA

    Orthotic Treatment of Diabetic Foot Ulcers

  • NCT05165745 · 175 participants · NA

    Stick2PrEP Cisgender Women and Trans Individuals

  • NCT05312255 · 175 participants · NA

    Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06782100, the US trial registry maintained by the National Library of Medicine. NCT06782100 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.